VITROLIFE GROUP

Press Release 24 January 2024 Gothenburg, Sweden

Conference call full year report 2023

Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2023. The presentation will be held in English.

Time: Friday 2 February, 2024 at 10.00 a.m. CET.

To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: <u>Privacy policy | Vitrolife Group</u>

Register for the call here

Vitrolife Group participants: Bronwyn Brophy O'Connor, CEO Patrik Tolf, CFO

The press release for the full year report will be released at 8.00 CET on the same day.

Before the conference call, presentation material will be available at the company web page.

A recorded version of the telephone conference will be available for seven days on number +44 (0) 20 3451 9993 (International), access code 4976448#.

Gothenburg, 24 January 2024 VITROLIFE AB (publ)

Contact:

Patrik Tolf, CFO, phone +46 (0)31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to enable people to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.